Full Text View
Tabular View
No Study Results Posted
Related Studies
Polyunsaturates and KCL to Control Mild Hypertension
This study has been completed.
Study NCT00000511   Information provided by National Heart, Lung, and Blood Institute (NHLBI)
First Received: October 27, 1999   Last Updated: June 23, 2005   History of Changes

October 27, 1999
June 23, 2005
December 1983
 
 
 
Complete list of historical versions of study NCT00000511 on ClinicalTrials.gov Archive Site
 
 
 
Polyunsaturates and KCL to Control Mild Hypertension
 

To test the efficacy of omega-3 fatty acids, magnesium, calcium, and potassium supplementation in untreated mild hypertensives and magnesium and potassium supplementation in treated hypertensives. Three clinical trials were conducted in sequence over a four year period.

BACKGROUND:

The hypothesis that omega-3 fatty acids as well as magnesium and potassium in the diet lowered blood pressure in mild hypertensives needed further documentation, although preliminary and less well controlled studies had suggested such an effect was possible. In a previous study the investigators did not find a hypotensive effect of another polyunsaturated fatty acid, linoleic acid. In addition, findings of lower blood pressures in vegetarians and results obtained from a study in which vegetarian diets were fed to normotensives led to the conclusion that dietary factors other then linoleic acid were responsible for the possible hypotensive effect of vegetarian diets. The nutrients which were selected for further study, omega-3 fatty acids, magnesium and potassium, occur in higher amounts in vegetarian diets.

Dietary supplementation with fish oils had only been done in a few studies with inconclusive results. However, the relationship of omega-3 fatty acids to the synthesis of prostacyclins, which are locally active vasodilators and which decrease with the excretion of the vasoconstrictor thromboxane, provide a possible mechanism for an effect of these compounds on blood pressure.

The role of potassium in the control of blood pressure was first suggested from cross-cultural studies in which populations consuming high levels of potassium displayed lower rates of hypertension and a decrease in blood pressure with age. Cohort studies within this country have also shown a relationship between potassium intake or the ratio of potassium and sodium, as measured by urinary excretion and blood pressure. Most constantly it found that blood pressure differences between blacks and whites have been related to differences in potassium excretion.

The results from human experimental studies involving potassium supplementation in normotensives and hypertensives have indicated mixed effects but blood pressure lowering was most consistently observed in subgroups with a family history of hypertension or those with higher blood pressure.

DESIGN NARRATIVE:

Trial 1: Subjects were randomized to a fish oil treatment group of 6 or 12 grams/day of omega-3 fatty acids or to a placebo group. At the end of 12 and 24 weeks, participants in the three groups were crossed-over to one of the other two treatments for an additional 12 weeks.

Trial 2: Subjects were randomly assigned to one of four treatments: magnesium plus calcium supplementation; potassium plus calcium supplementation; magnesium plus potassium supplementation; matching placebos. The trial was double-blinded. Each of the treatments was administered for six months with measurements taken every three months.

Trial 3: Similar to Trial 2. The primary endpoint in the three trials was change in diastolic blood pressure between baseline and the end of the studies based on an average of nine readings.

Phase II
Interventional
Treatment, Randomized, Crossover Assignment
  • Cardiovascular Diseases
  • Heart Diseases
  • Hypertension
  • Vascular Diseases
  • Behavioral: diet therapy
  • Drug: fatty acids, omega-3
  • Behavioral: dietary supplements
 
Morris MC, Taylor JO, Stampfer MJ, Rosner B, Sacks FM. The effect of fish oil on blood pressure in mild hypertensive subjects: a randomized crossover trial. Am J Clin Nutr. 1993 Jan;57(1):59-64.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
 
 

Mild hypertensives, ages 21 to 70, with no evidence of end-organ damage.. Untreated hypertensives.

Both
21 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00000511
 
30
National Heart, Lung, and Blood Institute (NHLBI)
 
 
National Heart, Lung, and Blood Institute (NHLBI)
March 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP